EP2297325A4 - Verfahren zur stratifizierung, prognose und diagnose von schizophrenie, mutierte nukleinsäuremoleküle und polypeptide - Google Patents

Verfahren zur stratifizierung, prognose und diagnose von schizophrenie, mutierte nukleinsäuremoleküle und polypeptide

Info

Publication number
EP2297325A4
EP2297325A4 EP09753383A EP09753383A EP2297325A4 EP 2297325 A4 EP2297325 A4 EP 2297325A4 EP 09753383 A EP09753383 A EP 09753383A EP 09753383 A EP09753383 A EP 09753383A EP 2297325 A4 EP2297325 A4 EP 2297325A4
Authority
EP
European Patent Office
Prior art keywords
prognosing
stratifying
polypeptides
methods
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09753383A
Other languages
English (en)
French (fr)
Other versions
EP2297325A1 (de
Inventor
Guy A Rouleau
Pierre Drapeau
Julie Gauthier
Claude Marineau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHUM
Original Assignee
CHUM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHUM filed Critical CHUM
Publication of EP2297325A1 publication Critical patent/EP2297325A1/de
Publication of EP2297325A4 publication Critical patent/EP2297325A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP09753383A 2008-05-29 2009-05-29 Verfahren zur stratifizierung, prognose und diagnose von schizophrenie, mutierte nukleinsäuremoleküle und polypeptide Withdrawn EP2297325A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5689108P 2008-05-29 2008-05-29
PCT/CA2009/000735 WO2009143622A1 (en) 2008-05-29 2009-05-29 Methods of stratifying, prognosing and diagnosing schizophrenia, mutant nucleic acid molecules and polypeptides

Publications (2)

Publication Number Publication Date
EP2297325A1 EP2297325A1 (de) 2011-03-23
EP2297325A4 true EP2297325A4 (de) 2011-10-05

Family

ID=41376517

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09753383A Withdrawn EP2297325A4 (de) 2008-05-29 2009-05-29 Verfahren zur stratifizierung, prognose und diagnose von schizophrenie, mutierte nukleinsäuremoleküle und polypeptide

Country Status (2)

Country Link
EP (1) EP2297325A4 (de)
WO (1) WO2009143622A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2571515B1 (de) 2010-05-17 2016-11-30 Icahn School of Medicine at Mount Sinai Verfahren und assays zur behandlung von patienten mit abbau, mutation oder reduzierter expression von shank3
RU2506595C2 (ru) * 2012-04-26 2014-02-10 Федеральное государственное бюджетное учреждение науки Институт биохимии и генетики Уфимского научного центра Российской академии наук (ИБГ УНЦ РАН) Способ прогнозирования риска развития параноидной шизофрении
JP2018110572A (ja) * 2017-01-13 2018-07-19 国立大学法人千葉大学 ＤＧＫδノックアウトマウス及びこれを用いた方法
CN108913757B (zh) * 2018-07-05 2021-06-11 广州市达瑞生物技术股份有限公司 一种染色体非整倍体数目异常的引物组与检测试剂盒及其应用
CN108841931B (zh) * 2018-07-05 2021-06-11 广州市达瑞生物技术股份有限公司 一种检测人4号染色体str基因座的引物组与检测试剂盒及其应用
US20240025984A1 (en) * 2020-11-06 2024-01-25 Flux Therapeutics, Inc. Cytosolic protein targeting deubiquitinases and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070281896A1 (en) * 2003-09-30 2007-12-06 Morris David W Novel compositions and methods in cancer
WO2009008896A1 (en) * 2007-07-06 2009-01-15 University Of Louisville Research Foundation, Inc. Genetic markers of schizophrenia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002523056A (ja) * 1998-08-18 2002-07-30 ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン Ｈｏｍｅｒ相互作用タンパク質
WO2000078921A2 (en) * 1999-06-24 2000-12-28 The Johns Hopkins University School Of Medicine Shank proteins and methods of use thereof
US8067160B2 (en) * 2007-07-06 2011-11-29 University Of Louisville Research Foundation, Inc. Genetic markers of schizophrenia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070281896A1 (en) * 2003-09-30 2007-12-06 Morris David W Novel compositions and methods in cancer
WO2009008896A1 (en) * 2007-07-06 2009-01-15 University Of Louisville Research Foundation, Inc. Genetic markers of schizophrenia

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE REFSEQ [online] XP002656892, retrieved from NCBI Database accession no. XP_589942 *
DATABASE REFSEQ [online] XP002656893, retrieved from NCBI Database accession no. XP_002688036 *
DUNHAM I ET AL: "THE DNA SEQUENCE OF HUMAN CHROMOSOME 22", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 402, no. 6761, 2 December 1999 (1999-12-02), pages 489 - 495, XP001180206, ISSN: 0028-0836, DOI: 10.1038/990031 *
HASHIMOTO ET AL: "SHANK proteins in the superior temporal cortex of patients with schizophrenia", SCHIZOPHRENIA RESEARCH, ELSEVIER, NETHERLANDS, vol. 60, no. 1, 15 March 2003 (2003-03-15), pages 63 - 64, XP005397336, ISSN: 0920-9964, DOI: 10.1016/S0920-9964(03)80574-1 *
See also references of WO2009143622A1 *

Also Published As

Publication number Publication date
WO2009143622A1 (en) 2009-12-03
EP2297325A1 (de) 2011-03-23

Similar Documents

Publication Publication Date Title
ZA201102252B (en) Methods and kits for nucleic acid sequencing
EP2254897A4 (de) Verfahren, reagentien und kits zum nachweis von nukleinsäuremolekülen
PL2326349T3 (pl) Nowe reagenty i sposób sprzęgania cząsteczek biologicznych
GB201014134D0 (en) Methods of RNA aplification in the presence of DNA
EP2227780A4 (de) Genetische analyse
GB0625070D0 (en) Characterization of molecules
PL1977225T3 (pl) Elektrochemiczny bioczujnikowy układ analityczny
EP2201021A4 (de) Alternative nukleinsäuresequenzierverfahren
EP2152911A4 (de) Melanomdiagnose mittels nukleinsäureanalyse
EP2359289A4 (de) Verfahren und systeme zur analyse von sequenzierungsdaten
WO2013066369A3 (en) Methods for detecting graft-versus-host disease
GB0805814D0 (en) Biosensor for analyte detection
EP2504348A4 (de) Verfahren, reagenzien und kits für den nachweis von nukleinsäuremolekülen
ZA201005791B (en) Rapid test including genetic sequence probe
EP2297325A4 (de) Verfahren zur stratifizierung, prognose und diagnose von schizophrenie, mutierte nukleinsäuremoleküle und polypeptide
GB0811500D0 (en) Method of determining DNA copy number
EP2318843A4 (de) Verfahren und kits zur vorhersage des einsetzens von geburtswehen
EP2250292A4 (de) Verfahren zur bestimmung der antibiotikaresistenz
EP2333552A4 (de) Neue biomarker für nichtalkoholische fettlebererkrankung und verfahren für den nachweis von nichtalkoholischer fettlebererkrankung mit einem biomarker
EP2288725A4 (de) Verfahren zur bestimmung von moleküleigenschaften
EP2240607B8 (de) Verfahren zum nachweisen und identifizieren von staphylokokken
WO2011041725A3 (en) Schizophrenia treatment response biomarkers
PL2358910T3 (pl) Sekwencje nukleotydów, sposoby i zestawy do wykrywania HPV
EP2252701A4 (de) Verfahren zur identifikation eines organismus
EP2202319A4 (de) Nukleinsäuresonde und verfahren zur herstellung eines sondenpolymers

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101229

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20110819BHEP

Ipc: G01N 33/68 20060101ALI20110819BHEP

Ipc: G01N 33/53 20060101ALI20110819BHEP

Ipc: C12Q 1/68 20060101ALI20110819BHEP

Ipc: C07K 14/78 20060101ALI20110819BHEP

Ipc: C07K 14/47 20060101ALI20110819BHEP

Ipc: C12N 15/12 20060101AFI20110819BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20110905

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20110829BHEP

Ipc: G01N 33/68 20060101ALI20110829BHEP

Ipc: G01N 33/53 20060101ALI20110829BHEP

Ipc: C12Q 1/68 20060101ALI20110829BHEP

Ipc: C07K 14/78 20060101ALI20110829BHEP

Ipc: C07K 14/47 20060101ALI20110829BHEP

Ipc: C12N 15/12 20060101AFI20110829BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MARINEAU, CLAUDE

Inventor name: GAUTHIER, JULIE

Inventor name: DRAPEAU, PIERRE

Inventor name: ROULEAU, GUY, A.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120403